#United States #Boston #Atopic Dermatitis #Bambusa Therapeutics #BBT001

Bambusa Therapeutics Takes a Major Step in Atopic Dermatitis Treatment

Bambusa Therapeutics, a rising name in biotechnology, has recently announced an exciting advancement in its clinical trial for BBT001, a novel therapy targeting atopic dermatitis. On October 1, 2026, the company reported that the first patient had been dosed in the subcutaneous (SC) cohort of its global Phase 1 clinical trial, marking a significant milestone in the development of this innovative treatment.

Background of BBT001

BBT001 is engineered as a half-life-extended bispecific antibody designed to block two significant pathways involved in atopic dermatitis: interleukin-4 receptor alpha (IL-4Rα) and interleukin-31 (IL-31). Atopic dermatitis (AD), a chronic inflammatory skin condition, affects many individuals worldwide, causing symptoms such as severe itchiness and irritation. The launch of subcutaneous dosing is part of Bambusa's effort to enhance patient outcomes through more convenient administration options.

Clinical Proof-of-Concept

Before the initiation of the SC dosing, Bambusa published compelling results from its intravenous (IV) treatment phase. In July 2026, they presented data showing that BBT001 led to rapid, deep, and lasting clinical improvements in skin conditions related to AD. After just one week, significant improvements were observed, deepening over time, ultimately leading to a recorded 79% reduction in the Eczema Area and Severity Index (EASI) by Week 6. Moreover, patients reported substantial relief from itchiness, with scores showing improvement as early as Day 1.

This transformative data underscores BBT001's potential not only in providing immediate relief but also in maintaining efficacy over time, making it a strong candidate for long-term management of atopic dermatitis. The trial demonstrated that Type 2 inflammatory biomarkers were significantly suppressed in patients, with effects lingering for eight weeks after the last dose.

Transitioning to Subcutaneous Dosing

Moving to subcutaneous dosing is a pivotal transition for Bambusa, as it strives to make treatment more patient-friendly. Dr. Thang Ho, Co-Founder and Chief Development Officer at Bambusa, emphasized the significant potential of BBT001. He noted that the prolonged half-life, combined with the solid clinical activity demonstrated in IV trials, lays a strong foundation for subcutaneous therapy. The goal is to ultimately provide a product that can be administered conveniently, potentially even once every three months, enhancing compliance and patient satisfaction.

The SC dosing cohort will consist of 45 biologic-naïve patients suffering from moderate-to-severe atopic dermatitis. Participants will receive five doses of the antibody, either at 360 mg or 720 mg, along with placebo control, over a 12-week period. Key evaluations will center around safety and tolerability, while secondary measures will include pharmacokinetics, assessing the longevity of BBT001 in the bloodstream, and immunogenicity.

Looking Ahead

As Bambusa Therapeutics progresses through this next phase, the company’s vision remains focused on delivering innovative, multi-targeting medicines that redefine patient care in chronic inflammatory diseases. The subcutaneous introduction of BBT001 not only reflects a strategic shift but also illustrates Bambusa's commitment to patient-centric treatment solutions. The results of this clinical trial may help cement BBT001's position as a leading contender in the evaluation and treatment of atopic dermatitis, signaling a new era in therapy where efficacy, durability, and convenience work hand in hand for improved patient outcomes.

Stay tuned as we follow Bambusa's journey with BBT001, with hopes that it will become a therapeutic cornerstone for millions affected by chronic skin diseases.

More About Bambusa Therapeutics

Bambusa is dedicated to developing ground-breaking therapies aimed at chronic immunological conditions. Its comprehensive research encompasses various aspects of protein engineering to ensure prolonged and effective treatments. With BBT001 on the forefront, they are looking to significantly enhance the quality of life for individuals with atopic dermatitis and beyond.